| 1718GCCC-S12 | A Randomized Phase 2 Trial of 28 Day (Arm A) versus 14 Day (Arm B) Schedule of Venetoclax (Ven) + Azacitidine (Aza) in newly diagnosed acute myeloid leukemia (AML) patients >/= 60 years | Open |
| 1718GCCC-S17 | A Phase 1b Dose Escalation and Expansion Study of SNDX-5613, azacitidine (Aza) and venetoclax (Ven) in newly diagnosed, untreated Acute Myeloid Leukemia (AML) Patients >/= 60 years with NPM1 mutated AML or Mixed Lineage Leukemia (MLL) Gene Rearrangements | Open |
| 1718GCCC-S21 | A Phase 1, Open-label, Dose Escalation and Dose Expansion, Multicenter Clinical Trial to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of ZE46-0134 in Adults with FLT3 mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) | Open |
| 2095GCCC | A Phase 1/2A First in Human Study of the Menin-MLL(KMT2A) Inhibitor KO-539 in Patients with Relapsed or Refractory Acute Myeloid Leukemia | Open |
| 22124GCCC | A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients with Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) not Eligible for Intensive Induction Chemotherapy | Open |
| 2254GCCC | A Phase 1, First-in-Human, Dose Escalation Study of MGD024, a CD123 x CD3 Bispecific DART Molecule, in Patients with Select Relapsed or Refractory Hematologic Malignancies | Open |
| 2282GCCC | A prospective randomized, double-blind, placebo-controlled, multi-center phase III study to evaluate the efficacy and safety of mocravimod as an adjunctive and maintenance treatment in adult acute myeloid leukemia (AML) patients undergoing allogeneic hematopoietic cell transplantation (HCT) | Open |
| 2321GCCC | Phase I clinical trial of the STING agonist CRD3874-SI in patients with relapsed/refractory acute myeloid leukemia, myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms | Open |
| 24101GCCC | A Phase 1/2, Open-Label, Dose-Escalation, Dose-Expansion Study of DSP-5336 in Adult Patients with Acute Leukemia and Other Selected Hematologic Malignancies, with and without Mixed Lineage Leukemia (MLL) rearrangement or Nucleophosmin 1 (NPM1) Mutation | Open |
| 24105GCCC | 24105GCCC: HP-00111968 "Registry and Biobank of Patients with a History of Cancer Therapy" | Open |
| 2458GCCC | Take the Reins: The effects of nutrient timing on cancer-related fatigue among blood cancer survivors | Open |